Last reviewed · How we verify
trimethoprim-sulfamethoxazole or doxycycline — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
trimethoprim-sulfamethoxazole or doxycycline (trimethoprim-sulfamethoxazole or doxycycline) — University of Texas Southwestern Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| trimethoprim-sulfamethoxazole or doxycycline TARGET | trimethoprim-sulfamethoxazole or doxycycline | University of Texas Southwestern Medical Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- trimethoprim-sulfamethoxazole or doxycycline CI watch — RSS
- trimethoprim-sulfamethoxazole or doxycycline CI watch — Atom
- trimethoprim-sulfamethoxazole or doxycycline CI watch — JSON
- trimethoprim-sulfamethoxazole or doxycycline alone — RSS
Cite this brief
Drug Landscape (2026). trimethoprim-sulfamethoxazole or doxycycline — Competitive Intelligence Brief. https://druglandscape.com/ci/trimethoprim-sulfamethoxazole-or-doxycycline. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab